PROMPt was a prospective cohort study evaluating point of care HCV antibody and RNA on testing rates and acceptability, linkage to care, and treatment in three priority settings: prison, an inpatient alcohol and drug unit, and inpatient mental health services in South Australia.  Study teams (composed of HCV-experienced nurses and peer educators) provided pre- and post-test counseling, harm reduction education, and administered point of care testing (POCT).  The HCV antibody screen utilized 10µl capillary whole blood; participants with positive antibody result were offered an RNA test (100µl capillary whole blood); participants with detectable HCV RNA were linked to care with the local viral hepatitis nurse service.  Among 1,549 participants, 98% indicated a preference for same-day HCV POCT compared to standard venipuncture and lab/instrument-based testing.  264 (17%) tested antibody positive and 100% underwent reflexive RNA testing, with 55 (4% overall, 21% of antibody-positive participants) testing RNA positive.  Across all three settings, there was an approximate three-fold increase in the rate of HCV antibody testing per year (and two-fold increase in RNA testing) in the intervention period compared to the historical control period, largely driven by increases in the inpatient alcohol and drug unit setting.  For the 55 RNA-positive participants, 91% were linked to care and 86% initiated treatment; median time from referral to treatment was 14 days.